<DOC>
	<DOCNO>NCT01218009</DOCNO>
	<brief_summary>This one-year study look safety dry powder inhaler albuterol . After one-week run , first 3 month subject use inhaler either albuterol dummy drug regular time four time day . Then last nine month study , subject give albuterol dry powder inhaler use need help breathing problem . Subjects need keep daily diary ( paper electronic ) throughout study record inhaler use health problem . There visit study doctor month year . This study intend show albuterol dry powder inhaler work well safe use long period time .</brief_summary>
	<brief_title>A Twelve Month Long Term Safety Study Evaluate Safety Albuterol Dry Powder Inhaler With Both Repeated Needed Dosing</brief_title>
	<detailed_description>The Sponsor terminate study due need modification Spiromax device utilize study ; problem identify impact patient safety . Exposure range 3 49 day majority subject receive â‰¤30 day double-blind treatment .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Documented history persistent asthma rescue use albuterol average least once/ week 4weeks prior screening . Female subject childbearing potential ( judged investigator ) must currently use willing continue use medically reliable method contraception entire study duration General good health Capable understanding requirement , risk , benefit study participation Nonsmoker least one year prior screen visit maximum packyear smoke history 10 year Other criterion apply Pregnancy , nursing , plan become pregnant donate gamete ( ova sperm ) vitro fertilization study period 30 day follow subject 's last study relate visit Participation investigational drug trial within 30 day precede screen visit A know hypersensitivity albuterol excipients formulation . History severe milk protein allergy History respiratory infection disorder ( include , limited bronchitis , pneumonia , acute chronic sinusitis , otitis medium , influenza , etc ) resolve within 1 week prior Screening Visit . Use protocol prohibit concomitant medication asthma protocol prohibit concomitant nonasthma medication Inability tolerate unwillingness comply protocol requirement . History lifethreatening asthma Any asthma exacerbation within 3 month Screening Visit require oral systemic corticosteroid History lifethreatening asthma Other criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>asthma</keyword>
	<keyword>dry powder inhaler</keyword>
	<keyword>short-acting beta2-agonist</keyword>
	<keyword>SABA</keyword>
	<keyword>bronchoconstriction</keyword>
	<keyword>bronchodilation</keyword>
	<keyword>bronchodilator</keyword>
	<keyword>meter dose inhaler</keyword>
</DOC>